APA (7th ed.) Citation

Lodi Rizzini, E., Zanoni, L., Tabacchi, E., Repaci, A., Scampoli, C., Vallerossa, D., . . . Monari, F. (2021). PO-1023 Impact of 18F-FDG-PET/CT in the management of suspected RAI refractory DTC persistence/recurrence. Radiotherapy & Oncology, 161, S851. https://doi.org/10.1016/S0167-8140(21)07474-0

Chicago Style (17th ed.) Citation

Lodi Rizzini, E., et al. "PO-1023 Impact of 18F-FDG-PET/CT in the Management of Suspected RAI Refractory DTC Persistence/recurrence." Radiotherapy & Oncology 161 (2021): S851. https://doi.org/10.1016/S0167-8140(21)07474-0.

MLA (9th ed.) Citation

Lodi Rizzini, E., et al. "PO-1023 Impact of 18F-FDG-PET/CT in the Management of Suspected RAI Refractory DTC Persistence/recurrence." Radiotherapy & Oncology, vol. 161, 2021, p. S851, https://doi.org/10.1016/S0167-8140(21)07474-0.